By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Media HydeMedia Hyde
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Font ResizerAa
Media HydeMedia Hyde
Font ResizerAa
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Follow US
© 2026 Media Hyde Network. All Rights Reserved.
Health

JPMC Forms Three-Member Inquiry Committee Over Alleged Data Falsification

Last updated: May 31, 2026 7:31 pm
Misbah Jogyat
Share
JPMC Forms Three-Member Inquiry Committee Over Alleged Data Falsification
JPMC Forms Three-Member Inquiry Committee Over Alleged Data Falsification
SHARE

The Jinnah Postgraduate Medical Centre (JPMC) in Karachi has launched a formal inquiry into allegations of research data manipulation, confirming the formation of a three-member committee to investigate the matter. The move follows internal reports suggesting that clinical data linked to recent research output was misrepresented.

Executive Director JPMC Dr. Shahid Rasool confirmed the committee’s mandate on Tuesday. The panel includes senior faculty members tasked with reviewing the integrity of the data in question and determining whether established research protocols were bypassed.

The investigation centers on a series of clinical studies conducted within the hospital’s research wing. Critics within the medical community have voiced concerns that the alleged discrepancies could compromise the facility’s academic standing and lead to the retraction of published findings. “We are looking into the veracity of the claims,” a senior hospital official said, speaking on condition of anonymity.

“If the data was indeed tampered with, the implications for the hospital’s research credibility are significant.” The committee is expected to cross-reference raw patient records against the published statistics.

They have been given a seven-day window to submit their findings. This is not the first time the premier public health institution has faced scrutiny over administrative and academic oversight. While the JPMC remains a cornerstone of medical training in Sindh, this inquiry marks a rare instance where the institution has publicly acknowledged potential internal misconduct regarding scientific integrity.

The hospital administration has declined to name the researchers involved, citing the ongoing nature of the investigation. Whether this committee produces a transparent resolution or follows the pattern of previous departmental probes remains the central question for the medical staff.

The committee’s report will determine if the matter remains an internal disciplinary issue or if it escalates to a legal review by the provincial health department.

Share This Article
Email Copy Link Print
Previous Article Healthy habits significantly cut chronic disease risks for childhood cancer survivors Healthy habits significantly cut chronic disease risks for childhood cancer survivors
Next Article Sharjeel Memon Slams IRSA Over ‘Unjust’ Cut in Sindh’s Water Share
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sponsored Ads

Stay Connected

FacebookLike
XFollow
InstagramFollow
YoutubeSubscribe
WhatsAppFollow
ThreadsFollow
How a Lost Road Helped Rewild a Rare Landscape
How a Lost Road Helped Rewild a Rare Landscape
Climate and Weather Headline
May 31, 2026
FBR Misses May Revenue Target by Rs28 Billion Despite Higher Collection
FBR Misses May Revenue Target by Rs28 Billion Despite Higher Collection
Business & Commerce
May 31, 2026
S.E.C. Proposes to Kill Climate Change Disclosure Rule
S.E.C. Proposes to Kill Climate Change Disclosure Rule
Climate and Weather Headline
May 31, 2026
MQM-P Warns of Citywide Protests Over Worsening Water Crisis in Karachi
Politics
May 31, 2026
Pakistan Plans Rs200bn Import-Duty Relief for Industry in FY2026-27 Budget
Business & Commerce
May 31, 2026
Sharjeel Memon Slams IRSA Over ‘Unjust’ Cut in Sindh’s Water Share
Politics
May 31, 2026

You Might Also Like

Health

5 Dry Fruits that Help Slow Aging and Boost overall Health

By
Irma Khan
Health

World Unites for a Polio-Free Future as Pakistan Reaffirms Commitment on World Polio Day

By
Irma Khan
WASHINGTON: UnitedHealth has warned that the Trump administration’s planned Medicare obesity-drug pilot faces “notable challenges,” casting doubt over how smoothly the program can move ahead if major insurers stay cautious. Recent market reporting said the model depends heavily on participation from Medicare drug plans that cover most Part D enrollees, which makes the stance of large insurers especially important. The concern centers on a broader CMS effort to expand access to GLP-1 weight-loss medicines for seniors. Under CMS’s published framework, the longer-term BALANCE Model would begin in Medicare Part D in January 2027, while a temporary Medicare GLP-1 Bridge is designed to start earlier and give eligible beneficiaries short-term access before that main model begins. What makes this a little more complicated is that the short-term bridge and the longer pilot are not the same thing. CMS says the Medicare GLP-1 Bridge operates outside the normal Part D coverage and payment flow, meaning Part D sponsors are not directly involved in that bridge arrangement. In other words, insurer participation is a much bigger issue for the 2027 BALANCE rollout than for the bridge itself. That distinction matters because investors and drugmakers are watching this closely. Reports said shares of obesity-drug makers fell after UnitedHealth’s comments, largely because Medicare coverage is seen as a huge growth opportunity for drugs such as Wegovy and Zepbound. If major insurers hesitate, the program could struggle to achieve the scale CMS appears to want. There is already some evidence of resistance. MarketWatch reported that CVS Health has opted out, while UnitedHealth is still evaluating the structure and discussing possible changes with Medicare officials. That does not mean the program is dead, not yet anyway, but it does suggest the administration may need to revise the design or sweeten the terms if it wants broader insurer buy-in. The bigger backdrop here is cost. Medicare has long been wary of broad obesity-drug coverage because GLP-1 therapies are expensive and potentially involve very large patient populations. Earlier policy debates around these drugs were shaped by concerns that wide coverage could drive up federal spending sharply, even as supporters argued the medicines could reduce longer-term health costs tied to obesity. So the headline problem for CMS is pretty straightforward: it has created a short-term bridge that can move without direct Part D plan involvement, but the more ambitious long-term Medicare model still appears to need insurers on board. UnitedHealth’s warning does not shut the door, but it does signal that one of the industry’s biggest players thinks the current setup may not be ready for easy launch.
HeadlineHealth

UnitedHealth raises red flags over Medicare obesity-drug pilot

By
Mabruka Khan
Health

Artificial Intelligence Discovers New Antibiotic Properties in Old Diabetes Drug

By
Neha Ashraf
Media Hyde Media Hyde Dark
Facebook Twitter Youtube Rss Medium

About US

Media Hyde Network: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 News.

Top Categories
  • Headline
  • Politics
  • Entertainment
  • Education
  • Sports
  • Religious
  • Metropolitan
  • Climate and Weather
Usefull Links
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Advertising Policy
  • Terms & Conditions

© 2025 Media Hyde Network. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?